Robotic exoskeleton technology. Photo courtesy of Kessler Foundation 2012
Robotic exoskeleton receives FDA clinical setting OK.
A robotic exoskeleton made by Ekso Bionics Holdings, Inc., has received the first U.S. Food and Drug Administration (FDA) clearance to be marketed for use with stroke patients in a clinical setting.
In addition to the treatment of individuals with hemiplegia because of stroke, the Ekso GT received clearance for use in the treatment of individuals with spinal-cord injuries at levels T-4 to L-5 and individuals with spinal-cord injuries at levels of T-3 to C-7 (American Spinal Injury Association classification D), in accordance with the device’s labeling.
Ekso GT is a wearable robotic exoskeleton that enables individuals to stand up and walk over ground with a full weight-bearing, reciprocal gait in a clinical setting.
The Ekso GT with smart Variable Assist software, which was designed for rehabilitation institutions, provides adaptive amounts of power to either side of the patient’s body, engaging the patient throughout his or her continuum of care.
The technology provides the ability to mobilize patients early in their recovery, frequently, with a significant number of high-intensity steps.